Filing Details

Accession Number:
0001415889-22-001742
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-23 20:23:45
Reporting Period:
2022-02-18
Accepted Time:
2022-02-23 20:23:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1800 Abbott Laboratories ABT Pharmaceutical Preparations (2834) 360698440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1783147 K Mary Moreland 100 Abbott Park Road
Abbott Park IL 60064
Executive Vice President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Without Par Value Acquisiton 2022-02-18 15,813 $0.00 88,158 No 4 A Direct
Common Shares Without Par Value Disposition 2022-02-22 793 $116.79 87,365 No 4 F Direct
Common Shares Without Par Value Disposition 2021-02-22 400 $119.31 86,965 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Option (right to buy) Acquisiton 2022-02-18 73,696 $0.00 73,696 $117.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,696 2023-02-18 2032-02-17 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares Without Par Value 10,986 Indirect Profit Sharing Trust
Footnotes
  1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
  4. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.